Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment

Two open‐label studies assessed the safety, tolerability, and pharmacokinetics of Oxbryta (voxelotor) in subjects with hepatic or renal impairment. Eight subjects with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m(2)) and 8 healthy age‐, sex‐, and body mass index...

Descripción completa

Detalles Bibliográficos
Autores principales: Preston, Richard A., Marbury, Thomas, Balaratnam, Ganesh, Green, Michelle, Dixon, Sandy, Lehrer‐Graiwer, Josh, Washington, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Editor's Choice: Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984382/
https://www.ncbi.nlm.nih.gov/pubmed/33084052
http://dx.doi.org/10.1002/jcph.1757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984382/
https://www.ncbi.nlm.nih.gov/pubmed/33084052
http://dx.doi.org/10.1002/jcph.1757

Ejemplares similares